Focken
Andreas Focken, Schwarzenbek DE
Patent application number | Description | Published |
---|---|---|
20080207342 | ROTATINGLY DRIVABLE CUTTING HEAD - A rotatingly drivable cutting head with at least one cutting insert, which has a cutting profile tool for radial engagement into a workpiece, the one axis of which is in the rotational axis of the cutting head, wherein cutting head and workpiece are moved axially and in the rotational direction with respect to each other, wherein the cutting insert is detachably attachable on a holding element of the cutting head, wherein further the holding element and with it the cutting insect is radially movable between a working position and a releasing position, and with locking means for positioning the cutting insert in the working position and shifting means for shifting the cutting insert from the working position into the releasing position and vice versa, wherein the cutting insert has an axis which runs parallel to the rotational axis in a distance, the cutting insert is attachable on the holding element in at least two rotational positions in an angular distance when it is rotated around its axis, and in every rotational position, a cutting profile tool is in the working position on the cutting insert. | 08-28-2008 |
20140311202 | Axial Thread Rolling Head and Method for Forming an External Thread on a Workpiece with an Axial Thread Rolling Head - The invention relates to an axial thread rolling head, comprising a head part, in which at least three thread rolls are rotatably mounted, wherein the thread rolls amongst themselves border an insertion section for a workpiece and wherein the thread rolls each have a profile for forming an outer thread on the workpiece, wherein the thread rolls are held non-adjustably in the radial direction in the head part, wherein the profile of the thread rolls is respectively designed asymmetrically such that the thread rolls with their asymmetrical profile form a symmetrical external thread on the workpiece. The invention also relates to a corresponding method. | 10-23-2014 |
Ingo Focken, Frankfurt Am Main DE
Patent application number | Description | Published |
---|---|---|
20110183998 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF - Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes. | 07-28-2011 |
20120282637 | POLYPEPTIDES FOR BINDING TO THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS AS WELL AS COMPOSITIONS AND METHODS INVOLVING - The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder. | 11-08-2012 |
Ingo Focken, Hochheim DE
Patent application number | Description | Published |
---|---|---|
20120244152 | NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF - The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion pheno-type. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used. | 09-27-2012 |
Ingo Focken, Hocheim DE
Patent application number | Description | Published |
---|---|---|
20140255305 | IMMUNO IMAGING AGENT FOR USE WITH ANTIBODY-DRUG CONJUGATE THERAPY - The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6. | 09-11-2014 |
20140256916 | IMMUNO IMAGING AGENT FOR USE WITH ANTIBODY-DRUG CONJUGATE THERAPY - The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6. | 09-11-2014 |
Thilo Focken, Burnaby CA
Patent application number | Description | Published |
---|---|---|
20130317000 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 11-28-2013 |
20130317001 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 11-28-2013 |
20140256736 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS - This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. | 09-11-2014 |